Today’s AI Top Pick: BESS

7/29/2026 · Low Float Bullish Consensus Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Low Float Bullish Consensus Deep RotationBESSBUY NOW8.4 / 107/29/2026

BESS (Bimergen Energy) is the cleanest intersection of fundamentals, forecast tape, and a fresh positive catalyst in this pool. It scores 13.5 (highest in the pool) with a fundamental_score of 6, fwdPe of just 2.39, strong buy recom of 1.0, and target upside of 223.9%. Crucially, on July 28 it announced receipt of $6.4M cash with another $2.5M contingent — real capital for a $21M market-cap utility, not a dilutive raise. That is a materially bullish, current catalyst rather than a stale narrative. The forecast tape confirms across the middle timeframes: 4h forecasts of +41.7% / +74.4% / +103.0% (short/mid/long) and 1d forecasts of +5.2% / +57.5% / +90.5%, all with bullish_prob = 1 and near_term_bullish = 0.8. Position in range on 4h and 1d is only 14.3% with drawdown of -38.8% from 21-bar highs — meaning we are buying into a deep pullback with the multi-timeframe model calling for a substantial mean-reversion higher, not chasing a top. That is exactly the setup the screen is designed to catch. The honest caveats: 1h pos_in_range is 94.3% (a small intraday extension) and weekly forecasts are essentially flat at -0.07%, so this is a 4h/1d trade, not a multi-month position. But compared to MORN (at 100% of range on every timeframe with negative near-term forecasts), TASK (also 100% of range), and IDN (better entry but weaker weekly forecast and recent bounce fizzling), BESS uniquely combines: strong fundamentals, deep intraday drawdown, positive cash-flow catalyst, RSI 40.5 (neutral, not overbought), debt/equity 0, and analyst upside >200%. Today is the right entry because the cash announcement is one day old and the 4h/1d model has not yet priced it in — waiting risks buying after gap-up momentum eats the pullback.

Entry zone

$2.95–$3.15 (scale in; take starter today ~$3.10, add on any dip toward $3.00)

Stop loss

$2.55 (below the -38.8% 4h/1d low; ~18% risk)

First target

$3.90 (roughly the 4h forecast mid ~+25% and reclaim of the 21-bar mid-range)

Longer target

$5.60–$6.00 (1d fc_long +90% territory; aligns with 4h fc_long +103%)

Risks

Utility micro-cap with ROE -30.72% and no revenue/margin disclosure — operational execution risk is high despite the $6.4M cash injection
Weekly forecasts are essentially flat (-0.07% across horizons), so the thesis is a 4h/1d swing, not a hold-through-earnings position
1h pos_in_range at 94.3% means near-term chasing risk — a red open could quickly retest $2.80
YTD performance -71.3% and 1-yr -53.0% show persistent seller supply; any bounce may face overhead resistance
Micro-float utility names can gap violently in either direction on low volume; size accordingly (this is not a full position)

Honorable mentions

IDNIntellicheck offers the best value + tape combo behind BESS: RSI 30.4 (oversold), pos_in_range only 0.2–8.6% across all timeframes, drawdowns of -14.5% to -57.1%, and 1h/4h forecasts of +40–162%. Fundamentals are legitimate (PE 33.6, gross margin 90.7%, positive profit margin 9.6%, salesYoY +15.3%, recom 1.67, debt/equity 0). The tradeoff: near_term_bullish only 0.4 and 1d fc_short is -5.06%, so this is more BUY_PULLBACK than BUY_NOW.

GRCEGrace Therapeutics got FDA meeting minutes on July 28 confirming 'no clinical safety or efficacy deficiencies' — a legitimate positive catalyst. Multi-timeframe pos_in_range is 3–35% (not extended), near_term_bullish 0.8, and 4h/1d forecasts show +42–58% mid/long. Lower fundamental score (2.25) than BESS/IDN, but the catalyst quality is real.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	BESS	BUY NOW	8.4	Cheapest fwdPe (2.39), fresh $6.4M cash catalyst, 4h/1d forecasts +57–103% with pos_in_range only 14%.
2	IDN	BUY NOW	7.6	Oversold RSI 30.4 with real revenue/profit, pos_in_range 0.2–8.6% and 1h forecasts +40/+105/+162%.
3	GRCE	BUY NOW	7.2	FDA Type A minutes confirm no deficiencies; near_term_bullish 0.8, 4h/1d fc_mid +45–55%.
4	LTRN	BUY NOW	6.9	EMA clearance for LP-184 Phase 1b/2 + patent allowance; deep dd -37.6% and near_term_bullish 0.8.
5	MBRX	BUY NOW	6.7	Positive MIRACLE readout narrative, near_term_bullish 1.0, 1d fc +50/+91/+190%; but recent -25% data-miss overhang.
6	TASK	BUY PULLBACK	6.4	Best real fundamentals (PE 5.46, profit margin 8.7%, ROE 26.5%) but pos_in_range 100% on 1h/4h/1d — wait for a dip.
7	TNXP	BUY PULLBACK	6.3	Medicare coverage expansion for TONMYA is a real catalyst; 1d fc_long +74% but weekly +8241% is a data outlier — don't overweight.
8	MORN	BUY PULLBACK	6.2	Strongest fundamentals (score 7.25) but pos_in_range 99–100% on every TF and short-term forecasts negative — chasing top.
9	DRMA	BUY NOW	5.9	Near_term_bullish 1.0 and 1d fc_long +217% with modest -11% drawdown; low fund quality but clean tape.
10	QNTM	BUY NOW	5.7	Near_term_bullish 1.0, 1d fc +23/+94/+100% and 4h dd -19.6% — micro-cap but multi-TF aligned.
11	BCDA	BUY PULLBACK	5.5	Deep -37% drawdown, pos_in_range ~0% and 1wk fc +140%; ROE -950% and salesYoY -100% is a landmine.
12	GLMD	BUY NOW	5.4	Aramchol Parkinson's and cardiac formulation catalysts, 4h/1d forecasts +38–108%, no debt.
13	XTLB	BUY PULLBACK	5.2	Only YTD-green name (+27.6%) with 1wk fc +90/+128% but pos_in_range 72–97% — extended.
14	NXL	BUY PULLBACK	4.9	Deep dd -40.98% weekly and 1d fc_mid/long +57/+86%, but 1d fc_short -8.93% and operating margin -3084%.
15	YCBD	BUY PULLBACK	4.8	Near_term_bullish 1.0 and RSI 26.4 oversold but pos_in_range 0% on 4h/1d/1wk suggests still falling knife.
16	NXTC	WAIT	4.7	Avere merger + $320M PIPE + CVR structure makes forecasts unreliable; recent +224% 1d spike distorts signals.
17	CNCK	BUY PULLBACK	4.6	1wk fc_mid/long +315%/+308% but fwdPe 1718 and 1h fc all negative — wait for confirmation.
18	AKTX	AVOID	4.5	Maxim upgrade & collaboration are positive but 1wk fc_short/mid/long all -100% is a hard tape red flag.
19	WW	WAIT	4.4	1d fc_long +76.9% but only 1 timeframe of data, D/E 1.76, and negative sales growth -9.6%.
20	HXHX	WAIT	4.3	PE 10.5 and profit margin 12% are decent but bullish_prob null and pos_in_range 0.13% shows persistent selling.
21	RGNT	BUY PULLBACK	4.2	Japan/EU regulatory wins are real, but only 2 TFs available and dd -61.5% shows structural weakness.
22	INTZ	WAIT	4.1	1d fc +59/+75% but 1h fc_short -8.4% and recent 'stock sinks' headline; ROE -123%.
23	ATRA	AVOID	3.8	1wk fc -85% across horizons, salesYoY -88%, pos_in_range 0% — tape says the pullback isn't done.
24	LUCY	AVOID	3.7	Claude AI headline is a positive but $3M warrant exercise = dilution; recom 3.0 (hold), profit margin -272%.
25	PRSO	AVOID	3.6	Near_term_bullish 1.0 undercut by $25M Roth equity line — dilution risk kills the setup.
26	IPWR	AVOID	3.4	$75M mixed-shelf filing is a dilution warning; P/S 2058 and profit margin -44,730% disqualifying.
27	USBC	AVOID	3.2	1d forecasts all negative (-52/-31/-20%) despite 1wk +1233% outlier; ROE -247% and profit margin blank.
28	CRE	WAIT	3.0	PE 6.55 is cheap but bullish_prob null and only 3 TFs; 1h fc all near zero/negative.
29	SSM	AVOID	2.6	P/S 72.4 and operating margin -5643% — target upside 1514% is fantasy.
30	QCLS	AVOID	1.8	Terminated Lightsolver license, 1wk forecasts -100% across horizons, bullish_prob 0 — broken.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord